Promoted Content

Promoted Content

X

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace

Market Place

Post Enquiry

Grow Your Pharma Business Digitally

Find Oncology Drugs in Phase I/II Clinical Development in NORWAY

All Data

Filters

refresh

×

FILTER DATA :

News Type

Company

Product Type

Deal Size

Upfront Payment

refresh

Product Type

Companies

Targovax

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

NORWAY Norway

Post An Enquiry

Virtual Innovation Day

Participation Not Confirmed

Update your events

Targovax Releases Presentations of ONCOS-102 Mesothelioma 24-Month Data

Contact the Supplier

Lead Product(s): ONCOS-102,Carboplatin,Cyclophosphamide

Therapeutic Area: Oncology Product Name: ONCOS-102

Highest Development Status: Phase I/ Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 14, 2021

Details:

ONCOS-102, an immune activators used in combination with Standard of Care (SoC) chemotherapy in patients with malignant pleural mesothelioma clearly shown tumor responses and survival outcomes.

Targovax